1. Home
  2. GRNQ vs GLTO Comparison

GRNQ vs GLTO Comparison

Compare GRNQ & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRNQ
  • GLTO
  • Stock Information
  • Founded
  • GRNQ 2013
  • GLTO 2011
  • Country
  • GRNQ Malaysia
  • GLTO Denmark
  • Employees
  • GRNQ N/A
  • GLTO N/A
  • Industry
  • GRNQ EDP Services
  • GLTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRNQ Technology
  • GLTO Health Care
  • Exchange
  • GRNQ Nasdaq
  • GLTO Nasdaq
  • Market Cap
  • GRNQ 8.9M
  • GLTO 6.5M
  • IPO Year
  • GRNQ 2018
  • GLTO 2020
  • Fundamental
  • Price
  • GRNQ $1.10
  • GLTO $4.61
  • Analyst Decision
  • GRNQ
  • GLTO Buy
  • Analyst Count
  • GRNQ 0
  • GLTO 1
  • Target Price
  • GRNQ N/A
  • GLTO $10.00
  • AVG Volume (30 Days)
  • GRNQ 80.2K
  • GLTO 20.5K
  • Earning Date
  • GRNQ 03-27-2025
  • GLTO 03-07-2025
  • Dividend Yield
  • GRNQ N/A
  • GLTO N/A
  • EPS Growth
  • GRNQ N/A
  • GLTO N/A
  • EPS
  • GRNQ N/A
  • GLTO N/A
  • Revenue
  • GRNQ $2,727,344.00
  • GLTO N/A
  • Revenue This Year
  • GRNQ N/A
  • GLTO N/A
  • Revenue Next Year
  • GRNQ N/A
  • GLTO N/A
  • P/E Ratio
  • GRNQ N/A
  • GLTO N/A
  • Revenue Growth
  • GRNQ N/A
  • GLTO N/A
  • 52 Week Low
  • GRNQ $0.80
  • GLTO $4.24
  • 52 Week High
  • GRNQ $2.24
  • GLTO $23.50
  • Technical
  • Relative Strength Index (RSI)
  • GRNQ 52.12
  • GLTO 40.91
  • Support Level
  • GRNQ $0.97
  • GLTO $4.24
  • Resistance Level
  • GRNQ $1.13
  • GLTO $5.25
  • Average True Range (ATR)
  • GRNQ 0.06
  • GLTO 0.35
  • MACD
  • GRNQ 0.01
  • GLTO -0.05
  • Stochastic Oscillator
  • GRNQ 84.11
  • GLTO 26.75

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management, cross-border listing advisory services, and transaction services. It also operates a venture capital business. Its segments include Service business engaged in the provision of corporate advisory and business solution services; and Real estate business engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: